Strata Critical Medical Inc

Strata Critical Medical Inc(SRTA)股票分析

$4.440

-0.290 (-6.53%)收盤時

Loading chart…
最高
4.725
開盤
4.700
成交量加權均價
4.52
成交量
1.11M
市值
—
最低
4.400
成交金額
5.02M
企業價值/稅息折舊攤銷前利潤(TTM)
-94.43

Strata Critical Medical, Inc. is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated one call solution for donor organ recovery. Its segments include Logistics and Clinical. Its core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands. The Company provides air and ground transportation of human organs for transplant as well as related staff, equipment, blood samples, and tissue samples. Its preservation services include operation of devices utilized to preserve organs prior to being transplanted into a recipient.

AI 分析 of Strata Critical Medical Inc (SRTA)

買進

Strata Critical Medical Inc (SRTA) is a good buy right now due to its recent strong earnings report showing a 15.1% sequential increase in clinical revenue for Q2 2026, reaching $24.3 million, and an upgraded EBITDA guidance of $33 million to $35 million for the year. The current price of $4.66 is attractive given the potential for significant upside, especially considering the projected trajectory based on similar historical patterns, which indicates a potential increase of 424.67%. However, investors should be cautious of the negative net income trend, with a reported loss of $10.5 million in Q2 2026, which poses a risk to profitability.

估值指標

Strata Critical Medical Inc(SRTA)目前預期本益比為 138.89,5 年平均預期本益比為 71.64。

預期本益比

合理
5 年均值 P/E
71.64
目前P/E
138.89
高估
150.50
低估
-7.21

預期 EV/EBITDA

合理
5 年均值 EV/EBITDA
87.94
目前EV/EBITDA
-94.43
高估
345.36
低估
-169.47

預期股價營收比

合理
5 年均值 P/S
1.41
目前P/S
1.29
高估
1.64
低估
1.18

持有 SRTA 的大戶

T

Third Point LLC

+ 持有SRTA

-4.02%

3個月報酬率

事件時間軸

2026-05-06 (ET)

07:40:00

Company Reports Q1 Revenue of $67.38M, Exceeding Expectations

07:40:00

Strata Adjusts FY26 EBITDA Guidance to $29M-$33M

2026-03-03 (ET)

07:10:00

Raises EBITDA Outlook to $29M-$33M

07:10:00

Will Heyburn: Company Aims for 30% Annual EBITDA Growth

2026-02-05 (ET)

08:50:00

Strata Critical Medical Enters $30M Credit Agreement with JPMorgan

資訊

SRTA 常見問題 —— 由 Alphio AI 解答

Strata Critical Medical, Inc. is a time-critical logistics and medical services provider to the United States healthcare industry. The Company operates air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated one call solution for donor organ recovery. Its segments include Logistics and Clinical. Its core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands. The Company provides air and ground transportation of human organs for transplant as well as related staff, equipment, blood samples, and tissue samples. Its preservation services include operation of devices utilized to preserve organs prior to being transplanted into a recipient. It operates in the Industrials sector.

Strata Critical Medical Inc (SRTA) is a good buy right now due to its recent strong earnings report showing a 15.1% sequential increase in clinical revenue for Q2 2026, reaching $24.3 million, and an upgraded EBITDA guidance of $33 million to $35 million for the year. The current price of $4.66 is attractive given the potential for significant upside, especially considering the projected trajectory based on similar historical patterns, which indicates a potential increase of 424.67%. However, investors should be cautious of the negative net income trend, with a reported loss of $10.5 million in Q2 2026, which poses a risk to profitability.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易